1: Saito A, Sakamoto M, Saito A, Ohmichi M, Hiraga Y, Kikuchi K, Ohsaki Y, Sasaki N, Matsumoto H, Suda T, Tsuzino M, Hirai Y, Inoue H, Yoshida M, Mouri T, Kobayashi H, Chiba S, Ito T, Moriya K, Bando T, Takeuchi K, Tanifuji Y, Shirato K, Tanno Y, Nakashima M, et al. [A comparative study on the efficacies of ritipenem acoxil and cefotiam hexetil in bacterial pneumonia by the double-blind method]. Jpn J Antibiot. 1996 Feb;49(2):144-74. Japanese. PubMed PMID: 8721077.
2: Poggesi I, Spinelli R, Frigerio E, Strolin Benedetti M, Carra L, Sassella D, Rimoldi R. A study of the pharmacokinetics and tolerability of ritipenem acoxil in healthy volunteers following multiple oral dosing. J Antimicrob Chemother. 1997 Aug;40(2):291-4. PubMed PMID: 9301999.
3: Saito A, Saito A, Kawakami Y, Yamaguchi E, Koba H, Abe S, Ohmichi M, Hiraga Y, Kikuchi K, Ohsaki Y, Matsumoto H, Inoue H, Yoshida M, Mouri T, Kobayashi H, Ito T, Bando T, Takeuchi K, Hirano H, Tanifuji Y, Tanno Y, Shirato K, Takahashi M, Sakamoto M, Nakashima M, et al. [Comparative study on the efficacy of ritipenem acoxil and cefotiam hexetil in chronic lower respiratory tract infections by the double-blind method]. Jpn J Antibiot. 1996 Mar;49(3):219-49. Japanese. PubMed PMID: 8935119.
4: Interpretation of the bacteriologic outcome of antibiotic treatment for uncomplicated cystitis: impact of the definition of significant bacteriuria in a comparison of ritipenem acoxil with norfloxacin. Swedish Urinary Tract Infection Study Group. Clin Infect Dis. 1995 Mar;20(3):507-13. PubMed PMID: 7756468.
5: Boersma WG, Puister SM, van Altena R, de Vries-Hospers HG, Molinari M, Koëter GH. Clinical and bacteriological efficacy and tolerability of FCE 22891 in patients with exacerbations of chronic obstructive pulmonary disease. Antimicrob Agents Chemother. 1994 Apr;38(4):872-5. PubMed PMID: 8031062; PubMed Central PMCID: PMC284559.